Save Article

The Canadian cannabis stocks we’ve weeded out have had an average stock price return of 87% year to date

SmallCapPower | December 4, 2019: Canadian licensed producers continued to see more selling action into the beginning of December. As a benchmark, the Horizons Marijuana Life Sciences Index (TSX:HMMJ) is down ~60% from its 2019 high of $23.65 on March 19, 2019. The all-time lows in the HMMJ index are being fueled by disappointing financials from Canopy Growth and Aurora Cannabis, which both posted sequential declines in revenues for CY/Q3. Aurora posted revenue of $75.2M, a 24% decline, while Canopy Growth posted revenue of $76.6M, a 15% decline. Both companies attributed poor top-line growth to blotched retail store roll-out in Ontario and Quebec. However, not all cannabis companies are alike, and some have managed to post positive return year to date. Today we have identified four Canadian cannabis stocks that have posted the biggest year-to-date gains.

*Share price data as at December 2, 2019, data obtained from S&P Capital IQ

For Our Complete Coverage Of Canadian Marijuana Stocks Click Here

Win Big With Our Small Cap Picks Leave this field empty if you're human:

MediPharm Labs Corp. (TSX:LABS) – $3.52

Cannabis Extraction

MediPharm Labs is the first company in Canada under the ACMPR without first receiving a cultivation license to become a licensed producer for cannabis oil production. MediPharm Labs produces purified, pharmaceutical-like cannabis oils and concentrates through its cGMP and ISO standard clean rooms laboratory. The Company currently has a 70,000 sq. ft. facility with 150,000 kg capacity and is planning to expand to 250,000 kg capacity by Q2/19. MediPharm Labs has invested in expert, state-of-the-art technology and extraction methods to deliver safe and precisely-dosed cannabis products to consumers and patients. On May 14, 2019, MediPharm Labs announced that it has entered into a multi-year supply agreement with Cronos Group Inc. It is expected that MediPharm Labs will supply Cronos Group with about $30M of cannabis concentrate over 18 months, and depending on renewal and purchase options, possibly up to $60M over 24 months.

Market Cap: $460.6M

30-Day Return: -23.6%

YTD-Return: +102.3%

30-Day Average Trading Volume: 1,470,880

Valens GroWorks Corp. (TSXV:VGW) – $3.02

Cannabis Extraction

Valens GroWorks is a pure-play cannabis extraction company with 425,000 kg of extraction capacity. Valens has signed extraction agreements with Organigram, Tilray, Canopy Growth, and HEXO Corp. Valens also has a strategic partnership with ThermoFisher Scientific, one of the world’s leading manufacturers of lab equipment, in addition to an ISO 17025 labs accreditation, which allows the Company to conduct standardized testing for over 400 different metals, pesticides, terpenes, residual solvents, microbials, and cannabinoid profiles.

Market Cap: $375.1M

30-Day Return: +1.3%

YTD-Return: +100.0%

30-Day Average Trading Volume: 320,570

Village Farms International, Inc. (TSX:VFF) – $8.30

Cannabis

Village Farms International is a vertically-integrated greenhouse grower in North America. The Company use hydroponic growing methods in glass-enclosed facilities to grow its premium-quality products. Currently, the Company has six greenhouses that cover a total of 9.2M sq.ft. As well, the Company has entered into the cannabis space with its joint ventures (JV) with Emerald Health Therapeutics and Nature Crisp LLC to create “Pure Sunfarms Corporation” and “Village Fields Hemp USA LLC,” respectively. On October 22, 2019, VFF completed its $28M bought deal at $9.40/share.

Market Cap: $434.9M

30-Day Return: -22.8%

YTD-Return: +87.8%

30-Day Average Trading Volume: 836,770

Trulieve Cannabis Corp. (CSE:TRUL) – $17.45

Cannabis

Trulieve is a seed-to-sale operation in the state of Florida, with plans to acquire additional facilities in Massachusetts, California, and Connecticut. The Company claims to be the largest, fully-licensed medical cannabis company in the State of Florida, with over 1.6M sq. ft of cultivation space yielding ~55,000 kg annually. Trulieve is in the process of constructing an additional 72,000 sq. ft, which would increase production capacity by 10,000 kg. TRUL also has a network of 37 dispensaries selling branded products, with a total of 240 stock keeping units (SKUs) and over 203,600 patients as of August 31, 2019. Trulieve is anticipating having 44 dispensaries open by year end.

Market Cap: $1,925.5M

30-Day Return: +30.2%

YTD-Return: +58.6%

30-Day Average Trading Volume: 273,240

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below:

DISCLAIMER

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.